This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Petz Aladar County Teaching Hospital
Győr, Hungary
RECRUITINGHospital S.M. Terni University of Perugia
Terni, Italy
COMPLETEDSamsung Medical Center
Seoul, South Korea
RECRUITINGNumber of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as any Adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after the last dose of study drug.
Time frame: up to approximately 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinica Universitad de Navarra
Pamplona, Spain
COMPLETEDGazi University Hospital Gazi University Faculty of Medicine
Ankara, Turkey (Türkiye)
RECRUITING